Cargando…

Ki-67 labeling index is a predictive marker for a pathological complete response to neoadjuvant chemotherapy in breast cancer: A meta-analysis

BACKGROUND: A pathological complete response (pCR) after neoadjuvant chemotherapy (NCT) is a strong indicator of the benefit of therapy and presents an early surrogate for a favorable long-term outcome. It remains unclear whether Ki-67, a marker for tumor proliferation, can function as a predictor o...

Descripción completa

Detalles Bibliográficos
Autores principales:	Tao, Miaomiao, Chen, Shu, Zhang, Xianquan, Zhou, Qi
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Wolters Kluwer Health 2017
Materias:	5750
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5758242/ https://www.ncbi.nlm.nih.gov/pubmed/29390540 http://dx.doi.org/10.1097/MD.0000000000009384

Ejemplares similares

Value of Breast Cancer Molecular Subtypes and Ki67 Expression for the Prediction of Efficacy and Prognosis of Neoadjuvant Chemotherapy in a Chinese Population
por: Wang, Jiayu, et al.
Publicado: (2016)

Neoadjuvant chemotherapy reduces the expression rates of ER, PR, HER2, Ki67, and P53 of invasive ductal carcinoma
por: Peng, Jian-Heng, et al.
Publicado: (2019)

Application of neoadjuvant chemotherapy in occult breast cancer: Five case reports
por: Yang, Haisong, et al.
Publicado: (2017)

Changes in HER2 status and survival outcomes in patients with non-pathological complete response after neoadjuvant targeted treatment
por: Ren, Xiaofei, et al.
Publicado: (2023)

Pathological complete response to neoadjuvant trastuzumab and pertuzumab therapy is related to human epidermal growth factor receptor 2 (HER2) amplification level in HER2-amplified breast cancer
por: Choi, Jin Hyuk, et al.
Publicado: (2020)

Management of the axilla with sentinel lymph node biopsy after neoadjuvant chemotherapy for breast cancer: A single-center study
por: Aksoy, Suleyman Ozkan, et al.
Publicado: (2020)

Neoadjuvant chemotherapy combined with endocrine therapy for hormone receptor-positive breast cancer: A systematic review and meta-analysis
por: Ma, Hong-Fang, et al.
Publicado: (2023)

High expression of MORC2 predicts worse neoadjuvant chemotherapy efficacy in triple negative breast cancer
por: Liao, Xiaohong, et al.
Publicado: (2023)

Background Parenchymal Enhancement on Preoperative Magnetic Resonance Imaging: Association With Recurrence-Free Survival in Breast Cancer Patients Treated With Neoadjuvant Chemotherapy
por: Choi, Ji Soo, et al.
Publicado: (2016)

Elevated expression of MTDH predicts better prognosis of locally advanced HER-2 positive breast cancer patients receiving neoadjuvant chemotherapy plus trastuzumab
por: Wang, Xinle, et al.
Publicado: (2019)

Adjuvant chemotherapy-associated lipid changes in breast cancer patients: A real-word retrospective analysis
por: He, Tao, et al.
Publicado: (2020)

Peripheral blood inflammatory indexes in breast cancer: A review
por: Xie, Jiaqiang, et al.
Publicado: (2023)

Triple mapping for axillary staging after neoadjuvant therapy: Axillary reverse mapping with indocyanine green and dual agent sentinel lymph node biopsy
por: Tasdoven, Ilhan, et al.
Publicado: (2022)

Combination of (125)I brachytherapy and chemotherapy for unresectable recurrent breast cancer: A retrospective control study
por: Tan, Qixing, et al.
Publicado: (2016)

Comparative efficacy and safety of metronomic chemotherapy in breast cancer: A protocol for network meta-analysis protocol
por: Xie, Ying, et al.
Publicado: (2021)

Ki-67 labeling index as a prognostic marker in advanced stomach cancer
por: Seo, Sang Hyuk, et al.
Publicado: (2019)

Acute arterial thrombosis during adjuvant Adriamycin-cyclophosphamide chemotherapy in a patient with early breast cancer: A case report
por: Jang, Lee Chan, et al.
Publicado: (2019)

Changes in ischemia-modified albumin in myocardial toxicity induced by anthracycline and docetaxel chemotherapy
por: Luan, Xiao-Dong, et al.
Publicado: (2017)

Nucleostemin expression in breast cancer is a marker of more aggressive phenotype and unfavorable patients’ outcome: A STROBE-compliant article
por: Sami, Manal M., et al.
Publicado: (2019)

Discordance of immunohistochemical markers between primary and recurrent or metastatic breast cancer: A retrospective analysis of 107 cases
por: Peng, Li, et al.
Publicado: (2020)

Expression profile of SIX family members correlates with clinic-pathological features and prognosis of breast cancer: A systematic review and meta-analysis
por: Xu, Han-Xiao, et al.
Publicado: (2016)

Efficacy and safety of Kanglaite injection combined with chemotherapy for women breast cancer: A protocol for systematic review and meta-analysis of randomized clinical trials
por: Cheng, Shengli, et al.
Publicado: (2021)

Chemotherapy-induced prospective memory impairment in breast cancer patients with different hormone receptor expression
por: Li, Wen, et al.
Publicado: (2017)

Long-term complete response to intrathecal trastuzumab in a patient with leptomeningeal carcinomatosis due to her2- overexpressing breast cancer: Case report
por: García, Francisco José Valdivia, et al.
Publicado: (2020)

Case report: 5-year progression free survival and complete liver response in a patient with metastatic breast cancer treated with everolimus plus exemestane
por: Krasniqi, Eriseld, et al.
Publicado: (2020)

Association of neutrophil-to-lymphocyte ratio with clinical, pathological, radiological, laboratory features and disease outcomes of invasive breast cancer patients: A retrospective observational cohort study
por: Jadoon, Sarosh Khan, et al.
Publicado: (2023)

Clinical study on Yanghe decoction in improving neo-adjuvant chemotherapy efficacy and immune function of breast cancer patients
por: Zhang, Xinyue, et al.
Publicado: (2022)

Combination of Chinese medicinal formulas and chemotherapy for triple-negative breast cancer strengthens body resistance to eliminate pathogenic factors
por: Zhang, Yiyi, et al.
Publicado: (2022)

In silico screening using bulk and single-cell RNA-seq data identifies RIMS2 as a prognostic marker in basal-like breast cancer: A retrospective study
por: Zhang, Lingyun, et al.
Publicado: (2021)

Assessment of Invasive Breast Cancer Heterogeneity Using Whole-Tumor Magnetic Resonance Imaging Texture Analysis: Correlations With Detailed Pathological Findings
por: Ko, Eun Sook, et al.
Publicado: (2016)

Ki-67 as a controversial predictive and prognostic marker in breast cancer patients treated with neoadjuvant chemotherapy
por: Ács, Balázs, et al.
Publicado: (2017)

Ki-67 as a Predictor of Response to Neoadjuvant Chemotherapy in Breast Cancer Patients
por: Kim, Kwan Il, et al.
Publicado: (2014)

Prognosis and clinicopathological characteristics of metaplastic breast cancer: A meta-analysis
por: Yang, Xiaolu, et al.
Publicado: (2022)

Magnetic resonance imaging and contrast-enhanced ultrasound findings of a recurrent primary breast angiosarcoma: A case report
por: Yang, Ou Ou, et al.
Publicado: (2021)

The effects of case management for breast cancer patients: A protocol for systematic review and meta-analysis
por: Chai, Yong, et al.
Publicado: (2022)

Prognostic significance of metabolic enzyme pyruvate kinase M2 in breast cancer: A meta-analysis
por: Yang, Yiming, et al.
Publicado: (2017)

Proliferation Marker Ki67 as a Stratification Index of Adjuvant Chemotherapy for Resectable Mucosal Melanoma
por: Tang, Lirui, et al.
Publicado: (2022)

Clinical Significance of Ki-67 Labeling Index in Pituitary Macroadenoma
por: Paek, Kyung-Il, et al.
Publicado: (2005)

Degree of Resection and Ki-67 Labeling Index for Recurring Meningiomas
por: Menger, Richard, et al.
Publicado: (2017)

The Associations of Single Nucleotide Polymorphisms in miR196a2, miR-499, and miR-608 With Breast Cancer Susceptibility: A STROBE-Compliant Observational Study
por: Dai, Zhi-Ming, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_j9hrtq74m4n22k9mro5nufjq8b